EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs

Sita Awasthi iD, Motoyasu Onishi iD, John M Lubinski, Bernard T Fowler, Alexis M Naughton, Lauren M Hook iD, Kevin P Egan, Masaki Hagiwara iD, Seiki Shirai, Akiho Sakai, Takayuki Nakagawa iD, Kumiko Goto und 6 weitere

Viruses · 2023

DOI: 10.3390/v15051148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Sita Awasthi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6073, USA. Hauptthemen laut MEDLINE: Herpes Genitalis, Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Shionogi & Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herpes simplex virus type 2 (HSV-2) is a leading cause of genital ulcer disease and a major risk factor for acquisition and transmission of HIV. Frequent recurrent genital lesions and concerns about transmitting infection to intimate partners affect the quality of life of infected individuals. Therapeutic vaccines are urgently needed to reduce the frequency of genital lesions and transmission. S-540956 is a novel vaccine adjuvant that contains CpG oligonucleotide ODN2006 annealed to its complementary sequence and conjugated to a lipid that targets the adjuvant to lymph nodes. Our primary goal was to compare S-540956 administered with HSV-2 glycoprotein D (gD2) with no treatment in a guinea pig model of recurrent genital herpes (studies 1 and 2). Our secondary goals were to compare S-540956 with oligonucleotide ODN2006 (study1) or glucopyranosyl lipid A in a stable oil-in-water nano-emulsion (GLA-SE) (study 2). gD2/S-540956 reduced the number of days with recurrent genital lesions by 56%, vaginal shedding of HSV-2 DNA by 49%, and both combined by 54% compared to PBS, and was more efficacious than the two other adjuvants. Our results indicate that S-540956 has great potential as an adjuvant for a therapeutic vaccine for genital herpes, and merits further evaluation with the addition of potent T cell immunogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes GenitalisVaccinesFemaleGuinea PigsAnimalsHerpesvirus 2, HumanAntibodies, NeutralizingAntibodies, ViralQuality of LifeViral Envelope ProteinsAdjuvants, ImmunologicGenitaliaLymph NodesDNA

Stichwörter der Autor:innen

HSV-2 DNA sheddingT cellsadjuvantgenital herpesglycoprotein Dguinea pigsherpes simplex virus type 2miceneutralizing antibodiestherapeutic vaccine

Substanzen

glycoprotein D-herpes simplex virus type 2Antibodies, NeutralizingAntibodies, ViralViral Envelope ProteinsVaccinesAdjuvants, ImmunologicDNA

Autor:innen und Institutionen

  • Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6073, USA.
  • Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka 561-0825, Japan.
  • Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6073, USA.
  • Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104-6073, USA.

ORCID-Profile: Sita Awasthi, Motoyasu Onishi, Lauren M Hook, Masaki Hagiwara, Takayuki Nakagawa, Grace Choi, Harvey M Friedman

Förderung

  • NIAID NIH HHS
  • Shionogi & Co., Ltd.

Zitieren

APA

Awasthi, S., Onishi, M., Lubinski, J. M., Fowler, B. T., Naughton, A. M., Hook, L. M., Egan, K. P., Hagiwara, M., Shirai, S., Sakai, A., Nakagawa, T., Goto, K., Yoshida, O., Stephens, A. J., Choi, G., Cohen, G. H., Katayama, K., & Friedman, H. M. (2023). Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs. Viruses. https://doi.org/10.3390/v15051148

Vancouver

Awasthi S, Onishi M, Lubinski JM, Fowler BT, Naughton AM, Hook LM, et al. Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs. Viruses. 2023. doi:10.3390/v15051148

BibTeX
@article{Awasthi2023,
  author = {Awasthi, Sita and Onishi, Motoyasu and Lubinski, John M and Fowler, Bernard T and Naughton, Alexis M and Hook, Lauren M and Egan, Kevin P and Hagiwara, Masaki and Shirai, Seiki and Sakai, Akiho and Nakagawa, Takayuki and Goto, Kumiko and Yoshida, Osamu and Stephens, Alisa J and Choi, Grace and Cohen, Gary H and Katayama, Kazufumi and Friedman, Harvey M},
  title = {Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15051148}
}
Kostenlos starten →